Related Experiment Videos
Peptichemio in neuroblastoma at relapse
Medical and Pediatric Oncology
|January 1, 1984
Summary
Peptichemio (PTC) showed antitumor activity in children with relapsed neuroblastoma, with 38% experiencing objective regression. Responses were better in patients not previously treated for relapse.
Area of Science:
- Pediatric Oncology
- Medical Chemistry
- Pharmacology
Background:
- Neuroblastoma is a common childhood cancer.
- Relapsed neuroblastoma presents significant treatment challenges.
- Novel therapeutic agents are needed for relapsed neuroblastoma.
Purpose of the Study:
- To evaluate the efficacy and toxicity of Peptichemio (PTC) in children with relapsed neuroblastoma.
- To determine objective response rates and factors influencing response to PTC.
Main Methods:
- A total of 39 children with relapsed neuroblastoma received PTC in two 5-day cycles.
- Dosages ranged from 1.0-1.5 mg/kg/day.
- Objective response was assessed based on standard criteria.
Main Results:
- Twenty-nine patients were evaluable for response.
- Subjective improvement was noted in 62% of patients.
- Objective regression occurred in 38% of patients (3% complete, 2% partial, 6% mixed).
- Higher response rates were observed in patients off therapy at relapse.
- Myelodepression and phlebosclerosis were the main toxicities.
Conclusions:
- Peptichemio (PTC) demonstrates objective antitumor activity in relapsed neuroblastoma.
- PTC is a potential treatment option for neuroblastoma patients at relapse.
- Further investigation into PTC's role in neuroblastoma treatment is warranted.